Drug evaluation in children 10 years after the European pediatric regulation current challenges and perspectives-Reference-Cited by-同舟云学术

Drug evaluation in children 10 years after the European pediatric regulation current challenges and perspectives

Published:2018-04 Issue:2 Volume:73 Page:113-117
ISSN:0040-5957
Container-title:Therapies
language:en
Short-container-title:Therapies

Author:

Élie Valery,Leroux Stéphanie,Kaguelidou Florentia,Jacqz-Aigrain Evelyne

Publisher

Elsevier BV

Subject

Pharmacology (medical)

Reference27 articles.

1. Unlicensed and off-label drug use in a paediatric ward of a general hospital in the Netherlands;Jong;Eur J Clin Pharmacol,2002

2. Survey of unlicensed and off label drug use in paediatric wards in European countries. European Network for Drug Investigation in Children;Conroy;BMJ,2000

3. La politique du médicament pour l’enfant en France et en Europe : enjeux et difficultés;Jacqz-Aigrain;Arch Pediatr,2009

4. Food and drug administration modernization act (FDAMA),1997

5. Best pharmaceuticals for children act. January 4, 2002. (Public Law No. 107-109) http://www.fda.gov/Drugs/DevelopmentApprovalProcess. [Accessed 18 January 2018].

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Development and performance of the c4c national clinical trial networks for optimizing pediatric trial facilitation;Frontiers in Pediatrics;2023-12-21

2. Développement des médicaments en pédiatrie : défis existants et recommandations;Therapies;2023-01

3. Paediatric drug development and evaluation: Existing challenges and recommendations;Therapies;2023-01

4. ADV6209 for Premedication in Pediatric Anesthesia: A Double-Blinded, Randomized Controlled Trial;Pharmaceutics;2022-09-27

5. c4c: Paediatric pharmacovigilance: Methodological considerations in research and development of medicines for children – A c4c expert group white paper;British Journal of Clinical Pharmacology;2021-12-18